April 30th 2024
A decision from the FDA is expected in the second half of 2024.
Advances In: Integrating New Treatment Options into Management Plans for Patients with Moderate-to-Severe Atopic Dermatitis
View More
Medical Crossfire®: Maximizing Patient Outcomes in Shingles – Are You Leveraging Guideline Based Care?
View More
"REEL" Time Patient Counseling™: Integrating Biosimilars into the Clinical Conversation
View More
PER Skin Summit: Optimizing Diagnosis and Individualizing Management of Hidradenitis Suppurativa
View More
Community Practice Connections™: 19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
View More
Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
View More
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Top 5 of 2016: Pediatric dermatology
December 5th 2016This year has seen many advancements in pediatric dermatologic care spanning inflammatory conditions to skin cancer as well as the nuances of these conditions in skin of color patients. These are the top 5 pediatric articles of 2016 from Dermatology Times.
Common pediatric disorders in skin of color
September 8th 2016Pediatric atopic dermatitis and acne have some similarities when these present in skin of color and lighter-skin children. But there are important differences when these common skin conditions affect darker skin types. An expert discusses how treatments should be approached.